Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $79.5252W HIGH $124.00
Volume
844.84 K
Value Traded
72.00 M
Short % Float
0.91%
Days to Cover
2.2
-2.18%Week
-5.1%1 Month
-6.55%3 Month
-3.66%6 Month
-53.35%5 Year
+458.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
21.65 B
EPS (TTM)
-5.87
P/E Ratio
-
Ent. Value
6.79 B
Total Shares
252.88 M
Float Shares
246.87 M
Insiders
0.43%
Institutions
19.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BNTX Catalyst Timeline
Dated clinical, regulatory and corporate events for BioNTech SE
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioNTech SE
743Total events
13Upcoming
273Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
PxB Fund makes first investment, launching and financing Emvena Therapeutics
▼Safety Data Updatetrastuzumab pamirtecanClinical Data
Higher ILD rate observed in DYNASTY-Breast02 vs prior trastuzumab pamirtecan trials
HR+/HER2-low metastatic breast cancersource ↗
▲Primary Endpoint Mettrastuzumab pamirtecanClinical Data
DYNASTY-Breast02 met primary PFS endpoint vs investigator's choice chemotherapy
HR+/HER2-low metastatic breast cancersource ↗
▲Topline Readouttrastuzumab pamirtecanClinical Data
Topline results of DYNASTY-Breast02 Phase 3 trial announced
HR+/HER2-low metastatic breast cancersource ↗
▲Late-BreakerPumitamigPresentation
Late-breaking oral presentation of ROSETTA Lung-107 data at ESMO Congress 2026
metastatic non-small cell lung cancer (NSCLC)source ↗
▲Topline ReadoutPumitamigClinical Data
First data from Phase 2 ROSETTA Lung-107 of pumitamig plus docetaxel in 2L NSCLC
metastatic non-small cell lung cancer (NSCLC) after progression on immunotherapy plus chemotherapysource ↗
●Poster PresentationPumitamigPresentation
ePoster presentation of ROSETTA Gastric-204 Phase 2/3 trial design for 1L pumitamig plus chemotherapy at ESMO 2026
gastric cancer, gastroesophageal junction adenocarcinoma, esophageal adenocarcinomasource ↗
●Poster Presentationelfetabart drozuntecanPresentation
Poster presentation of BNT324-03 Phase 3 trial design for elfetabart drozuntecan in taxane-naive mCRPC at ESMO 2026
metastatic castration-resistant prostate cancersource ↗
●Poster PresentationBNT317Presentation
Poster presentation of preclinical antitumor activity for anti-PD-1×CD39 bispecific BNT317 at ESMO 2026
●Poster PresentationBNT329Presentation
Poster presentation of first-in-human Phase 1/2 trial design for BNT329 (CA19-9 ADC) at ESMO 2026
advanced solid tumors expressing CA19-9source ↗
▲Partnership / LicensePumitamigCorporate
BioNTech enters clinical trial collaboration and supply agreement with Gilead for pumitamig plus sacituzumab govitecan
PD-L1 low or negative triple-negative breast cancersource ↗
▼Primary Endpoint MissedBNT113Clinical Data
BNT113 plus pembrolizumab missed PFS dual primary endpoint vs pembrolizumab alone
HPV16-positive head and neck squamous cell carcinomasource ↗
●DSMB ReviewBNT113Trial
IDMC recommended AHEAD-MERIT continue to evaluate OS endpoint
HPV16-positive head and neck squamous cell carcinomasource ↗
▼Topline ReadoutBNT113Clinical Data
First topline results from AHEAD-MERIT Phase 2/3 trial of BNT113 plus pembrolizumab
HPV16-positive head and neck squamous cell carcinomasource ↗
▲Oral PresentationGotistobartPresentation
Updated PRESERVE-003 stage 1 data presented at IASLC 2026 WCLC
squamous non-small cell lung cancersource ↗
▲Topline ReadoutGotistobartClinical Data
First median OS data from non-pivotal stage 1 of PRESERVE-003 presented at WCLC 2026
squamous non-small cell lung cancersource ↗
▲Primary Endpoint MetGotistobartClinical Data
Statistically significant and clinically meaningful OS benefit in stage 1 of PRESERVE-003
squamous non-small cell lung cancersource ↗
▲Supplemental ApprovalFDA Decision
FDA approved sBLA for monovalent XFG-adapted COVID-19 vaccine for adults 65+ and at-risk individuals 5-64
COVID-19source ↗
▲EU ApprovalBNT162b2ApprovedEx-US Regulatory
European Commission grants marketing authorization for XFG-adapted COVID-19 vaccine
COVID-19source ↗
▲Product LaunchBNT162b2ApprovedPost-Market
Shipping of XFG-adapted vaccine to begin soon
COVID-19source ↗
▲EU ApprovalEx-US Regulatory
European Commission grants marketing authorization for XFG-adapted COVID-19 vaccine for 2026-2027 season
COVID-19source ↗
▲Product LaunchPost-Market
Shipping to begin imminently for XFG-adapted vaccine in EU
COVID-19source ↗
▲CHMP Positive OpinionBNT162b2ApprovedEx-US Regulatory
EMA CHMP recommended approval of XFG-adapted vaccine
COVID-19source ↗
▲CHMP Positive OpinionEx-US Regulatory
CHMP recommended approval of XFG-adapted COVID-19 vaccine
COVID-19source ↗
●Enrollment UpdateGotistobartTrial
87 patients randomized in stage 1 of PRESERVE-003 as of data cut-off
squamous non-small cell lung cancersource ↗
◆IP Litigation RulingIP / Competition
Arbutus and Genevant file three international patent infringement lawsuits against Pfizer and BioNTech
◆Equity OfferingCorporate
Arbutus expects to return up to ~$230M to shareholders via share repurchases
▲Partnership / LicenseCorporate
BMS collaboration revenue of €613 million expected in Q3 2026
▲Full ResultsGotistobartClinical Data
Gotistobart data showing nearly doubled median OS versus chemotherapy in previously treated squamous NSCLC
squamous non-small cell lung cancersource ↗
●Full ResultsPumitamigClinical Data
First global data for pumitamig plus elfetabart drozuntecan in lung cancer
lung cancersource ↗
▲EU ApprovalEx-US Regulatory
European Commission approved monovalent XFG-adapted COVID-19 vaccine
COVID-19source ↗
▲Product LaunchPost-Market
Launch of variant-adapted COVID-19 vaccine for 2026/2027 vaccination season
COVID-19source ↗
◆Poster Presentationtrastuzumab pamirtecanPresentation
Phase 3 trial of trastuzumab pamirtecan (HER2 ADC) vs chemo in HER2-expressing recurrent EC
recurrent endometrial cancersource ↗
◆Poster PresentationPumitamigPresentation
Phase 2/3 trial of pumitamig + chemotherapy vs bevacizumab + chemotherapy in 1L CRC
Colorectal cancersource ↗
◆Poster PresentationBNT324/DB-1311Presentation
Phase 3 trial of BNT324/DB-1311 (B7H3 ADC) vs docetaxel in taxane-naïve mCRPC
Metastatic castration-resistant prostate cancersource ↗
◆Oral PresentationPumitamigPresentation
Phase 2 data from ROSETTA Lung-02 for pumitamig + chemo in 1L NSCLC
first-line non-small cell lung cancersource ↗
●Enrollment UpdatePumitamigTrial
Phase 3 part of ROSETTA Lung-02 currently recruiting
non-small cell lung cancersource ↗
●Trial InitiationPumitamigTrial
ROSETTA Lung-201 Phase 3 trial currently enrolling
non-small cell lung cancersource ↗
◆Oral PresentationGotistobartPresentation
Overall survival for patients with pre-treated PROC receiving gotistobart + pembrolizumab
Platinum-resistant ovarian cancersource ↗
◆Poster PresentationBNT326/YL202Presentation
Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig
advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How BNTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-31 | BNT113 | Phase 3 interim results | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
32
Drugs Scored
rNPV / MCap
Top Drug
Top 3%
Mid Cap(rank 22 of 687)
Percentile Rank
Commercial products (revenue basis: latest annual revenue in its 20-F, converted from EUR to USD, to Dec 2025; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| COVID-19 vaccine |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BNT323 Antibody-Drug Conjugates (ADCs)NCT06340568 | Endometrial Cancer | Phase 3 | RECRUITING | 480 | Nov 1, 2029 | ||||||
| BNT323 Antibody-Drug Conjugates (ADCs)NCT06018337 | Metastatic Breast Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 541 | Aug 1, 2028 | ||||||
| BNT323 Antibody-Drug Conjugates (ADCs)NCT05150691 | HER2-positive Advanced Solid Tumor | Phase 1/2 | RECRUITING | 796 | Oct 1, 2027 | ||||||
| BNT323 Antibody-Drug Conjugates (ADCs)NCT06827236 | Locally Advanced Breast Cancer | Phase 1/2 | RECRUITING | 380 | Aug 1, 2029 | ||||||
| Pumitamig BiologicsNCT07173751 | Breast Neoplasms | Phase 3 | RECRUITING | 558 | Sep 1, 2030 | ||||||
| Pumitamig BiologicsNCT06419621 | Triple Negative Breast Cancer(TNBC) | Phase 3 | ACTIVE NOT_RECRUITING | 392 | Jul 1, 2028 | ||||||
| Pumitamig BiologicsNCT06449209 | Extensive-stage Small-cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 731 | Feb 1, 2028 | ||||||
| Pumitamig BiologicsNCT05879068 | SCLC | Phase 3 | ACTIVE NOT_RECRUITING | 553 | Apr 30, 2026 | ||||||
| Pumitamig BiologicsNCT06841055 | Non-small Cell Lung Cancer | Phase 2/3 | RECRUITING | 1,640 | Oct 1, 2028 | ||||||
| Pumitamig BiologicsNCT05756972 | NSCLC | Phase 2 | ACTIVE NOT_RECRUITING | 64 | Dec 1, 2025 | ||||||
| Pumitamig BiologicsNCT06449222 | Locally Advanced Breast Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 83 | Jun 1, 2029 | ||||||
| Pumitamig BiologicsNCT05918133 | TNBC | Phase 1/2 | ACTIVE NOT_RECRUITING | 42 | Oct 30, 2026 | ||||||
| Pumitamig BiologicsNCT06584071 | HCC | Phase 1/2 | NOT YET_RECRUITING | 140 | Dec 1, 2027 | ||||||
| Pumitamig BiologicsNCT05918445 | Malignant Neoplasm | Phase 1/2 | RECRUITING | 380 | Nov 30, 2025 | ||||||
| Pumitamig BiologicsNCT07133750 | CRC (Colorectal Cancer) | Phase 2 | RECRUITING | 100 | May 1, 2030 | ||||||
| Pumitamig BiologicsNCT07255404 | Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | RECRUITING | 105 | Aug 1, 2028 | ||||||
| Pumitamig BiologicsNCT07297212 | Recurrent Glioblastoma | Phase 2 | RECRUITING | 75 | Jul 1, 2029 | ||||||
| Pumitamig BiologicsNCT05879055 | Neuroendocrine Neoplasm | Phase 2 | ACTIVE NOT_RECRUITING | 31 | Jan 1, 2028 | ||||||
| Gotistobart BiologicsNCT05671510 | Non Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 630 | Aug 31, 2028 | ||||||
| BNT168 BiologicsNCT07698600 | HIV -1 Infection | Phase 1 | RECRUITING | 126 | Feb 1, 2028 | ||||||
| BNT324 Small MoleculesNCT07365995 | Metastatic Castration-resistant Prostate Cancer | Phase 3 | RECRUITING | 736 | Feb 1, 2031 | ||||||
| BNT324 Small MoleculesNCT05914116 | Advanced Solid Tumors | Phase 1/2 | RECRUITING | 862 | May 1, 2028 | ||||||
| BNT324 Small MoleculesNCT06953089 | Solid Tumors | Phase 2 | RECRUITING | 750 | Jun 30, 2030 | ||||||
| BNT324 BiologicsNCT06892548 | Advanced Lung Cancer | Phase 1/2 | RECRUITING | 594 | May 1, 2032 | ||||||
| BNT116 BiologicsNCT05142189 | Non-Small Cell Lung Cancer | Phase 1 | RECRUITING | 320 | Nov 1, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every BNTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| trastuzumab pamirtecan | HR+/HER2-low metastatic breast cancer | Phase 3 | 2026-10-26 | statistically significant, yet modest improvement in progression-free survivalRead More | BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sahin UgurOfficer (Chief Executive Officer), 10% Owner | Sell | -36,209 | $95.37 | 10/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BNTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Logos Global Management LP | 4.1 % (28.1 %) | 94.45 M | 1.01 M | 407.5% ( 815.00 K) |
Ownership Trends
BNTX Short Interest
Shares sold short, counted twice a month.
0.91%
Short % of Float
of tradable shares sold short
2.2M
Shares Sold Short
-1.2% vs prior count
2.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BNTX ranks across every disease it competes in
Competitive Position is a premium feature
See how BNTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBNTX News
BNTXPenn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment
The Penn-BioNTech Innovative Therapeutics Seed Fund has invested in Emvena Therapeutics, which focuses on placenta-targeted mRNA medicines for serious maternal and fetal conditions. Emvena's lead program targets preeclampsia, a significant complication affecting pregnancies. The fund aims to support the translation of University of Pennsylvania research into viable treatments.
Read more →BNTXBioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
BioNTech reported third quarter 2026 revenues of €1,289.2 million, a decrease from the previous year. The company raised its full-year revenue guidance to €1.7–1.9 billion, citing strong performance in oncology and COVID-19 vaccine sales. Notable clinical advancements include a global Phase 3 trial for pumitamig in triple-negative breast cancer.
Read more →BNTXBioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
BioNTech and DualityBio announced that their DYNASTY-Breast02 Phase 3 trial met its primary endpoint, showing a statistically significant improvement in progression-free survival for trastuzumab pamirtecan in HR+/HER2-low metastatic breast cancer. However, a higher incidence of interstitial lung disease was reported, and the overall survival data remains immature. Next steps will be discussed based on these findings.
Read more →BNTXBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
BioNTech and Bristol Myers Squibb reported promising Phase 2 data for pumitamig in advanced non-small cell lung cancer (NSCLC). The combination with docetaxel achieved a confirmed objective response rate of 36.7% and a median progression-free survival of 6.9 months. This trial addresses a significant unmet need for patients post-immunotherapy and chemotherapy.
Read more →BNTXBioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
BioNTech announced a collaboration with Gilead to advance the ROSETTA Breast-01 trial, evaluating pumitamig with sacituzumab govitecan for treating PD-L1 low or negative triple-negative breast cancer. This trial aims to replace chemotherapy with an antibody-drug conjugate, reflecting the evolving treatment standards. The combination is expected to improve patient outcomes significantly.
Read more →BNTXBioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
BioNTech SE will announce its financial results for Q3 2026 on November 3, 2026. The company will also host a conference call and webcast for investors and analysts to discuss these results and provide a corporate update. The event is accessible via registration, and a replay will be available afterward.
Read more →BNTXBioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
BioNTech will present new clinical data from its oncology pipeline at ESMO 2026, including results from the Phase 2 ROSETTA Lung-107 trial evaluating pumitamig in metastatic non-small cell lung cancer. The company will also showcase data on pumitamig's combination with elfetabart drozuntecan in advanced solid tumors. These findings underscore the potential of pumitamig across various tumor types and treatment settings.
Read more →BNTX▼ -7.1%on this news
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
BioNTech's AHEAD-MERIT Phase 2/3 trial for BNT113 in metastatic HPV16-positive head and neck cancer did not achieve its primary endpoint of progression-free survival. However, the trial will proceed to assess overall survival, which could still yield a positive outcome. The mRNA immunotherapy aims to enhance treatment for patients with limited options.
Read more →BNTXBioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
BioNTech and OncoC4 reported updated data from the PRESERVE-003 Phase 3 trial, showing that gotistobart significantly improves median overall survival in previously treated squamous non-small cell lung cancer patients. The investigational treatment achieved a median survival of 18.5 months compared to 10.0 months with standard chemotherapy. This data suggests a promising shift in treatment options for patients facing limited alternatives.
Read more →BNTX▼ -8.4%on this news
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Pfizer and BioNTech have received FDA approval for their new COVID-19 vaccine formula designed to target the XFG variant. This approval aligns with FDA guidance to ensure the vaccine matches currently circulating variants. Shipping of the vaccine will commence immediately, facilitating rapid access for the upcoming season.
Read more →BNTXBioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
BioNTech SE is showcasing its advancements in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer. Key highlights include the first clinical data for a novel combination of pumitamig and elfetabart drozuntecan, as well as updated survival data for gotistobart from the PRESERVE-003 Phase 3 trial. The company is committed to addressing unmet medical needs in lung cancer through a diversified clinical pipeline.
Read more →BNTXBioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
BioNTech SE reported its second quarter 2026 financial results, highlighting the appointment of Guido Oelkers as CEO and the initiation of six pivotal clinical trials. The company achieved several milestones, including the approval of a new COVID-19 vaccine variant. However, it also faced challenges with a significant net loss and decreased revenues due to lower demand for its vaccines, prompting a revision of its financial guidance for the year.
Read more →BNTXBioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
BioNTech has appointed Guido Oelkers as its new CEO, effective by February 1, 2027. Oelkers, who has over 30 years of experience in the biotechnology sector, succeeds Prof. Ugur Sahin. His appointment follows a comprehensive selection process and is expected to enhance BioNTech's growth and innovation in the biopharmaceutical industry.
Read more →BNTXEuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
The European Commission has authorized Pfizer and BioNTech's 2026-2027 COVID-19 vaccine, which targets the XFG variant. This decision follows a recommendation from the EMA's Emergency Task Force, citing strong immune responses against current SARS-CoV-2 lineages. The vaccine is approved for individuals aged six months and older, with manufacturing already underway to meet anticipated demand.
Read more →BNTXBioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
BioNTech SE will announce its financial results for the second quarter of 2026 on August 4, 2026. A conference call and webcast will be held at 8:00 a.m. ET to discuss these results and provide a corporate update. The event is open to investors and the public, with materials available on the company's website.
Read more →BNTXGlobal Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
BioNTech and Bristol Myers Squibb announced promising interim Phase 2 data from the ROSETTA Lung-02 trial, showing high response rates for the bispecific immunomodulator pumitamig in patients with advanced non-small cell lung cancer. The trial demonstrated significant anti-tumor activity across different PD-L1 expression levels, with manageable safety profiles. The companies are advancing further studies to evaluate pumitamig's efficacy.
Read more →BNTXBioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
BioNTech will present new clinical data from its late-stage oncology pipeline at the 2026 ASCO Annual Meeting. Key highlights include promising results for pumitamig in non-small cell lung cancer and gotistobart in platinum-resistant ovarian cancer. The company is advancing over 25 Phase 2 and Phase 3 trials, focusing on innovative treatment combinations.
Read more →BNTXBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
BioNTech SE held its Annual General Meeting where shareholders approved all agenda items, including the expansion of the Supervisory Board. New members with expertise in oncology and clinical development were elected. The company aims to enhance its late-stage oncology pipeline while continuing early research efforts.
Read more →BNTXBioNTech Announces New ADS Repurchase Program
BioNTech has announced a new share repurchase program allowing for the repurchase of up to $1 billion in American Depositary Shares until May 6, 2027. This initiative is part of the company's strategy to enhance capital efficiency and support long-term growth. The program will be funded using existing cash resources and is designed to operate within regulatory safe harbors.
Read more →BNTXUNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Interim Condensed Consolidated Statements of Profit or Loss 1 Interim Condensed Consolidated Statements of Comprehensive Income 2 Interim Condensed Consolidat
BioNTech SE has released its unaudited interim condensed consolidated financial statements for the three months ended March 31, 2026. The company reported a net loss of €531.9 million, a decline from €415.8 million in the same period last year. Revenues also fell significantly, amounting to €118.1 million compared to €182.8 million in the prior year. Additionally, total assets decreased from €21,988.6 million to €21,074.1 million over the same time frame.
Read more →About BioNTech SE
BIOPHARMAWATCH ELITE
Trade the next BNTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime